DEAL ANNOUNCEMENT
McDermott Represents Valinor Pharma in $250 Million Sale to Grünenthal
July 23, 2024
Read time: 3 min
McDermott Will & Emery represented Valinor Pharma, LLC (Valinor), a pharmaceutical company focused on the commercialization of medicines, in a cross-border sale to Grünenthal, a German-based global leader in pain management and related diseases. The total deal value is approximately $250 million inclusive of all royalty obligations and includes Valinor’s product Movantik®, an oral treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, which achieved over $200 million in gross U.S. sales in 2023.
The McDermott team was led by Kristian Werling and included John Zukin, Dane Christensen, Marisa Montoya, Kate Vera, Lauren Sawyer, Gregory Heltzer, Ty Carson, Scott Kenkel, Alex Farr, Jamie Ravitz, Marissa Hill Daley, Jim Nicholas and Caitlin Harrington.
Read Grünenthal’s announcement of the transaction.
This is McDermott’s second specialty pharmaceuticals deal in the last year, following the Firm’s representation of Vanda Pharmaceuticals Inc. in its acquisition of PONVORY®, a treatment for adults with relapsing forms of multiple sclerosis (RMS), from Johnson & Johnson in December 2023.
McDermott’s global Life Sciences Group operates as a cross-border, interdisciplinary team, drawing upon lawyers from the top-ranked healthcare law practice to work at the juncture of health, technology and life sciences. Among th4e team’s recent notable work, after three years of hard-fought litigation over foundational cancer testing patents, McDermott secured back-to-back wins on behalf of Natera, a global leader in cell-free DNA testing, and a Delaware jury awarded the company $19.35 million. The team also recently represented WindRose Health Investors in the acquisition of SubjectWell, the patient access marketplace that connects people with health conditions to care options.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media contact
McDermott Advises Main Capital Partners on Take-over of US-based DevOps software provider Flexagon
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advises Main Capital Partners on Take-over of US-based DevOps software provider Flexagon
July 23, 2024
Read time: 3 min
Chicago/Düsseldorf, July 23, 2024 – McDermott Will & Emery has advised Main Capital Partners on the acquisition of Flexagon, a leading US-based software provider of DevOps solutions for the enterprise sector.
Founded in 2014 in Green Bay, Wisconsin, Flexagon is a leading provider of DevOps software for complex enterprise technology environments such as Oracle, SAP, and Salesforce. With around 40 employees, Flexagon achieves an average growth rate of 25% per year.
Main Capital Partners is a leading software investor in the Benelux, DACH, the Nordics, and the United States with approx. EUR 6 billion in assets under management. Operating with 75 employees from its offices in The Hague, Düsseldorf, Stockholm, Antwerp, and an affiliated office in Boston Main maintains an active portfolio of over 45 software companies.
The McDermott team included partners Christopher Stacker, Jeffrey M. Holdvogt, Gregory M. Weigand, Dustin Schwerdtfeger, counsel Deepali Doddi as well as associates Yuxin Jin, Scott Kenkel, Eleanor B. Atkins and Melis Solaksubasi.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
“We have built up a strong client base”
COVERAGE
“We have built up a strong client base”
July 23, 2024
Read time: 2 min
Dr. Matthias Kampshoff and Dr. Jens Ortmanns discussed the full-service offering and strategy of McDermott Will & Emery in Germany and the next stages of the firm’s development in an interview with Börsen-Zeitung.
Media Contact
Deal Watch: What Does Biden’s Exit Mean for the Deal Market?
COVERAGE
Deal Watch: What Does Biden’s Exit Mean for the Deal Market?
July 22, 2024
Read time: 2 min
Media Contact
ITU Applicants Beware: Federal Courts Have Jurisdiction Over Pending Trademark Applications
COVERAGE
ITU Applicants Beware: Federal Courts Have Jurisdiction Over Pending Trademark Applications
July 22, 2024
Read time: 2 min
Media Contact
1 Year at the UPC: Implications for Transatlantic Disputes
COVERAGE
1 Year at the UPC: Implications for Transatlantic Disputes
July 17, 2024
Read time: 3 min
Last month, the Unified Patent Court (UPC) celebrated its one-year anniversary after it launched in 17 countries across Europe. During this time, it has significantly impacted many industries and fields, including medical devices, pharmaceuticals and various electronics. Decisions on key issues have undoubtedly contributed to the UPC’s growth, already establishing the new court as a popular venue for patent disputes.
In this article, Chuck Larsen, Aashish Kapadia and Charles de Raignac explore the significant decisions that are shaping the court’s direction, particularly in transatlantic disputes. Patent holders should be aware of these decisions and stay attuned of upcoming decisions that will continue to develop the UPC’s law and practice and shape its future usage.
Karen Gover contributed to the development of this article.
Media Contact
McDermott Advises KRÜGER GROUP on the Acquisition of Hermes Süssstoff
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advises KRÜGER GROUP on the Acquisition of Hermes Süssstoff
July 19, 2024
Read time: 3 min
Düsseldorf, July 19, 2024 – McDermott Will & Emery has advised the Germany-based KRÜGER GROUP on the acquisition of Hermes Süssstoff AG based in Zurich, Switzerland.
The KRÜGER GROUP and its subsidiaries have long been active along the entire production chain for sweeteners and have a global network. With the acquisition of Hermes Süssstoff AG from the Klosterfrau Healthcare Group, the KRÜGER GROUP has further expanded its position in the field of calorie-free sweeteners.
The KRÜGER GROUP based in Bergisch Gladbach is a globally established family business in the food industry. KRÜGER develops, produces and markets its products with around 5,600 employees at 21 locations in ten countries. The Group owns brands such as KABA, Schogetten, Trumpf, Fritt and Hafervoll.
The Hermes Süssstoff AG was founded in 1904 and distributes and produces the internationally renowned brands Hermesetas and SteviaSweet in addition to the sweetener Assugrin.
The transaction has already been completed. Business operations of Hermes Süssstoff will continue unchanged after the acquisition.
McDermott regularly advises the KRÜGER GROUP on international transactions and on national and international antitrust and competition issues.
The McDermott team advising the KRÜGER Group comprised partners Thomas Ammermann, Christian Krohs and Paul McGrath as well as counsel Marcus Fischer and associate Julian Rößler-Weis.
Media Contact
McDermott advises HF Private Debt-backed BioneXX on Sale of BeLive to USP Group
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott advises HF Private Debt-backed BioneXX on Sale of BeLive to USP Group
July 19, 2024
Read time: 3 min
Munich, July 19, 2024 – McDermott Will & Emery represented HF Private Debt-backed BioneXX Holding GmbH on the sale of its subsidiary Nat4Life America Inc, known under the BeLive brand, to the USP Group.
BioneXX, headquartered in Frankfurt/Main, Germany, offers a wide range of natural food supplements and organic phytovitamins and is a market leader in Germany, France, Austria and Switzerland with its Feelgood Shop, GSE and Fitne brands. With the sale of BeLive, the company intends to focus on its core market in Europe
The USP Group, founded and based in the USA, has been active in the consumer health sector since 1990. The company has commercial operations in 12 European countries and two production facilities in Poland and Sweden.
The McDermott team was led by partner Holger H. Ebersberger, and comprised partner Steffen Woitz and associate Manuel Weiß.
Media Contact
SAIGroup’s Acquisition of Get Well
COVERAGE
SAIGroup’s Acquisition of Get Well
July 18, 2024
Read time: 2 min
Media Contact
Legal Updates: Crossover Beverage Guidance Takes Shape, DTC Laws Advance
COVERAGE
Legal Updates: Crossover Beverage Guidance Takes Shape, DTC Laws Advance
July 18, 2024
Read time: 2 min
